S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
NASDAQ:ADIL

Adial Pharmaceuticals - ADIL Stock Forecast, Price & News

$0.31
-0.01 (-3.12%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.30
▼
$0.34
50-Day Range
$0.20
▼
$0.37
52-Week Range
$0.20
▼
$2.62
Volume
256,641 shs
Average Volume
190,196 shs
Market Capitalization
$8.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Adial Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
864.6% Upside
$3.00 Price Target
Short Interest
Healthy
0.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Adial Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.51) to ($0.32) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

See Top Rated MarketRank™ Stocks Here

ADIL stock logo

About Adial Pharmaceuticals (NASDAQ:ADIL) Stock

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.

Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADIL Stock News Headlines

November 16, 2022 | seekingalpha.com
Adial Pharmaceuticals GAAP EPS of -$0.12 beats by $0.06
October 4, 2022 | finance.yahoo.com
Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate
January 29, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
September 28, 2022 | benzinga.com
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5030 as a Potential Treatment for Chronic Pain
September 26, 2022 | finance.yahoo.com
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain
September 26, 2022 | finance.yahoo.com
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain
September 22, 2022 | seekingalpha.com
ADIL Adial Pharmaceuticals, Inc.
September 6, 2022 | nasdaq.com
Adial Pharma Says Purnovate's PNV-6005 Reports Positive Data In Treating Ulcerative Colitis
January 29, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
September 6, 2022 | finance.yahoo.com
Adial Pharma's Subsidiary Shows Encouraging Preclinical Action For Inflammatory Bowel Disease Candidate
September 6, 2022 | finance.yahoo.com
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis
September 1, 2022 | finance.yahoo.com
Here's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom Fisher
August 29, 2022 | finance.yahoo.com
Zacks.com featured highlights include Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight Enterprises
August 23, 2022 | seekingalpha.com
Adial Clinical Trial: A Fluff Or A Win?
August 18, 2022 | uk.investing.com
Adial Pharmaceuticals Provides Business Update, Reports Q2
August 17, 2022 | seekingalpha.com
Adial gets cut at Maxim on need for capital to map path for alcohol disorder drug
August 16, 2022 | finance.yahoo.com
Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
August 16, 2022 | finance.yahoo.com
Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
July 20, 2022 | finance.yahoo.com
EXCLUSIVE: Adial Pharma's AD04 Effective In Heavy Drinker Alcohol Use Disorder Patients
July 20, 2022 | seekingalpha.com
Adial stock slumps 25% as AD04 fails to best placebo in very heavy drinkers in trial
July 20, 2022 | finance.yahoo.com
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder
July 18, 2022 | finance.yahoo.com
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
June 28, 2022 | finance.yahoo.com
Adial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley
June 27, 2022 | finance.yahoo.com
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
June 14, 2022 | seekingalpha.com
Adial gets US patent linked to AD04, diagnostic test for alcohol/opioid use disorder
June 14, 2022 | finance.yahoo.com
Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
June 14, 2022 | finance.yahoo.com
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence
See More Headlines
Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADIL Company Calendar

Last Earnings
11/14/2022
Today
1/29/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADIL
CUSIP
N/A
CIK
1513525
Web
www.adialpharma.com
Phone
(434) 422-9800
Fax
N/A
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+864.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-19,420,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-227.60%
Return on Assets
-156.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.10
Quick Ratio
5.10

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.17 per share
Price / Book
1.83

Miscellaneous

Outstanding Shares
25,850,000
Free Float
19,680,000
Market Cap
$8.04 million
Optionable
Not Optionable
Beta
0.60

Key Executives

  • Cary J. Claiborne
    President, Chief Executive Officer & Director
  • Joseph Truluck
    Chief Financial Officer, Secretary & Treasurer
  • Bankole A. JohnsonBankole A. Johnson
    Chief Medical Officer
  • Julien Dimastromatteo
    Vice President-Research
  • Alex Lugovoy
    Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













ADIL Stock - Frequently Asked Questions

Should I buy or sell Adial Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADIL shares.
View ADIL analyst ratings or view top-rated stocks.

What is Adial Pharmaceuticals' stock price forecast for 2023?

2 brokers have issued twelve-month price targets for Adial Pharmaceuticals' shares. Their ADIL share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 864.6% from the stock's current price.
View analysts price targets for ADIL or view top-rated stocks among Wall Street analysts.

How have ADIL shares performed in 2023?

Adial Pharmaceuticals' stock was trading at $0.2150 at the beginning of 2023. Since then, ADIL stock has increased by 44.7% and is now trading at $0.3110.
View the best growth stocks for 2023 here.

Are investors shorting Adial Pharmaceuticals?

Adial Pharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 144,500 shares, an increase of 12.3% from the December 31st total of 128,700 shares. Based on an average daily trading volume, of 140,900 shares, the short-interest ratio is presently 1.0 days.
View Adial Pharmaceuticals' Short Interest.

When is Adial Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our ADIL earnings forecast.

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) issued its earnings results on Monday, November, 14th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.06.

What other stocks do shareholders of Adial Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP).

When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $0.31.

How much money does Adial Pharmaceuticals make?

Adial Pharmaceuticals (NASDAQ:ADIL) has a market capitalization of $8.04 million. The company earns $-19,420,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The official website for the company is www.adialpharma.com. The company can be reached via phone at (434) 422-9800 or via email at investor_relations@haynesintl.com.

This page (NASDAQ:ADIL) was last updated on 1/29/2023 by MarketBeat.com Staff